Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01253603 | Efficacy, Safety, and Pharmacokinetics of QAW039 | PHASE2 | COMPLETED | 170 | — | — | Nov 1, 2010 | Sep 1, 2011 | Dec 19, 2020 | 26 | United States, Belgium +3 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAW039 capsules once daily for 28 days |
| 2 | EXPERIMENTAL | Placebo to QAW039 capsules once daily for 28 days |
| 3 | EXPERIMENTAL | Fluticasone propionate inhaler twice daily for 28 days |
| Name | Type | Description |
|---|---|---|
| QAW039 capsules once daily for 28 days | DRUG | - |
| Placebo to QAW039 capsules once daily for 28 days | DRUG | - |
| Fluticasone propionate inhaler twice daily for 28 days | DRUG | - |
Inclusion Criteria: * Patients with a medical history of mild to moderate persistent allergic asthma. * Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of \>17 kg/m2. * Female patients must be surgically sterilized, postmenopausal or using a doub...